Home / Market News / $GOSS
benzinga Corporate Catalyst Impact 65/100 ● neutral

Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160

Oct 13, 2026, 7:31 PM UTC · Primary ticker $GOSS

Chardan Capital initiated coverage on Gossamer Bio (GOSS) with a 'Buy' rating and a significant price target of $160. This analyst coverage and high price target could generate positive sentiment and increased investor interest in GOSS, potentially leading to a short-term stock price increase.

Chardan Capital analyst Andreas Argyrides initiated coverage on Gossamer Bio (GOSS) with a 'Buy' rating and a $160 price target. This is a significant event for GOSS as new analyst coverage, especially with a 'Buy' rating and a high price target, often signals increased institutional interest and can act as a positive catalyst for the stock. This could lead to short-term upward price movement as investors react to the perceived validation and future growth potential. The long-term implications depend on the company's execution and whether it can meet the analyst's expectations. A key opportunity for traders is to capitalize on potential short-term momentum, but the risk lies in the stock already pricing in some of this news or failing to sustain the positive sentiment.

$GOSS positive New 'Buy' rating and high price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.